December 21, 2000
Genta Licenses New Platform Technology From National Institutes Of Health
December 14, 2000
Genta Signs Genasense<sup>TM</sup> Manufacturing And Supply Agreement With Avecia
December 4, 2000
Multiple Myeloma Reported Responsive to Bcl-2 Antisense Treatment
December 4, 2000
Investigators Report clinical Activity Of Genta's Lead Antisense Drug In Acute Leukemia
November 17, 2000
Genta's Lead Antisense Drug Reported Active In Malignant Melanoma
November 13, 2000
Investigators Report Activity for Genasense<sup>TM</sup> , Genta's Lead Antisense Compound In Combination Therapy For Prostate Cancer
November 10, 2000
Genta Raises $28 Million In Equity Placement
November 2, 2000
Genta Incorporated Announces Thrid Quarter Results
October 16, 2000
Genta's CEO Outlines The Company's Program In Hematology At Meeting Of The Leukemia Society
October 10, 2000
Genta Announces Appointment Of Distinguished Scientists To Advisory Board
October 2, 2000
Genta Raises $14.6 Million In Private Placement
September 28, 2000
Genta Announces Licensing Deal For Antisense Technology To Oasis Biosciences
September 19, 2000
Genta's CEO Presents Updated Clinical Trials Results and Proposed New Clinical Trials at Anticancer Conference
August 9, 2000
Genta's CEO Discusses Product Pipeline And Partnership Plans In Interview With CEOcast.com
August 7, 2000
Genta Announces Orphan Drug Designation From Food and Drug Administration And Completes Strategic Review For Its Lead Compound, Genasense<sup>TM</sup>
August 7, 2000
Genta Incorporated Announces Second Quarter 2000 Results
August 1, 2000
Genta Announces Licensing Deal For Antisense Technology To Sequitur
July 27, 2000
Genta Announces the Hiring Of Paul F. Manley, Formerly of Johnson & Johnson, As New Vice President Of Regulatory Affairs
July 27, 2000
Genta's Lead Antisense Drug Genasense<sup>TM</sup> Enhances Activity Of Chemotherapy In Mouse Model Of Human Breast Cancer
July 13, 2000
Genta Added to Russell 2000 Index
July 11, 2000
Genta Launches Follow-up Studies Of Genasense<sup>TM</sup> Combination Therapy For Prostate Cancer At Major Cancer Centers
June 7, 2000
Genta's Lead Antisense Drug Boosts Lymphoma Chemotherapy Investigators Report Complete Eradication Of Human Lymphoma In Mouse Model
June 5, 2000
Genta and Molecular Biosystems Announce Licensing Deal For Key Antisense Technology
May 24, 2000
Investigators At ASCO Meeting Report Activity With Genta's Antisense Drug, Genasense<sup>TM</sup> (G3139), Plus Chemotherapy In Men With Advanced Prostate Cancer
May 23, 2000
Investigator At ASCO Meeting Define Mechanism Of Antisense Action For Genta's Lead Drug
May 23, 2000
Results with Genta's Antisense Drug, Genasense<sup>TM</sup> (G3139), Plus Taxol<sup>TM</sup> Presented At ASCO Meeting
May 22, 2000
Expanded Clinical Role for Genta's Antisense Drug Advocated At ASCO Educational Sessions
May 22, 2000
Investigators At ASCO Meeting Report Activity With Genta's Antisense Drug, Genasense<sup>TM</sup> (G3139), Plus Chemotherapy In Women With Advanced Breast Cancer
May 4, 2000
Genta Gains Listing On Nasdaq National Market System
May 3, 2000
Genta Incorporated Announces First Quarter 2000 Results and Simplification Of Its Capital Structure
April 14, 2000
Major Progress In Aggressive Cancer Type Reported For Genta's Lead Antisense Drug
April 5, 2000
Genta Announces Significant Progress In Small Molecule Program For Treatment Of Prostate Cancer
April 4, 2000
Investigator Reports Major Antitumor Activity With Genta's Antisense Product G3139 In Malignant Melanoma
March 30, 2000
Major Progress Reported In Aggressive Cancers For Genta's Lead Antisense Drug
March 9, 2000
Genta Launches Pivotal Registration Study Of Its Lead Antisense Compound In Malignant Melanoma
February 4, 2000
Genta Announces Grant Of Four Key Patents For Its Next Generation Antisense Technologies
February 3, 2000
Genta Incorporated Announces Fourth Quarter And Year-End 1999 Results
January 18, 2000
Genta Announces Election Of Distinguished Cancer Specialist, Dr. Daniel D. Von Hoff, to Board Of Directors
January 5, 2000
NCI Commences Trial Of Genta's Bcl-2 Antisense Compound Combined With Paclitaxel For Relapsed Small Cell Lung Cancer
